Vanessa Y. Zhang , Shayna L. O’Connor , William J. Welsh , Morgan H. James
{"title":"预测 Orexin 1 受体配体结合亲和力的机器学习模型","authors":"Vanessa Y. Zhang , Shayna L. O’Connor , William J. Welsh , Morgan H. James","doi":"10.1016/j.aichem.2023.100040","DOIUrl":null,"url":null,"abstract":"<div><p>The orexin 1 receptor (OX1R) is a G-protein coupled receptor that regulates a variety of physiological processes through interactions with the neuropeptides orexin A and B. Selective OX1R antagonists exhibit therapeutic effects in preclinical models of several behavioral disorders, including drug seeking and overeating. However, currently there are no selective OX1R antagonists approved for clinical use, fueling demand for novel compounds that act at this target. In this study, we meticulously curated a dataset comprising over 1300 OX1R ligands using a stringent filter and criteria cascade. Subsequently, we developed highly predictive quantitative structure-activity relationship (QSAR) models employing the optimized hyper-parameters for the random forest machine learning algorithm and twelve 2D molecular descriptors selected by recursive feature elimination with a 5-fold cross-validation process. The predictive capacity of the QSAR model was further assessed using an external test set and enrichment study, confirming its high predictivity. The practical applicability of our final QSAR model was demonstrated through virtual screening of the DrugBank database. This revealed two FDA-approved drugs (isavuconazole and cabozantinib) as potential OX1R ligands, confirmed by radiolabeled OX1R binding assays. To our best knowledge, this study represents the first report of highly predictive QSAR models on a large comprehensive dataset of diverse OX1R ligands, which should prove useful for the discovery and design of new compounds targeting this receptor.</p></div>","PeriodicalId":72302,"journal":{"name":"Artificial intelligence chemistry","volume":"2 1","pages":"Article 100040"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949747723000404/pdfft?md5=43fcbc13b8cafbb292e0ad47efa38a38&pid=1-s2.0-S2949747723000404-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Machine learning models to predict ligand binding affinity for the orexin 1 receptor\",\"authors\":\"Vanessa Y. Zhang , Shayna L. O’Connor , William J. Welsh , Morgan H. James\",\"doi\":\"10.1016/j.aichem.2023.100040\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The orexin 1 receptor (OX1R) is a G-protein coupled receptor that regulates a variety of physiological processes through interactions with the neuropeptides orexin A and B. Selective OX1R antagonists exhibit therapeutic effects in preclinical models of several behavioral disorders, including drug seeking and overeating. However, currently there are no selective OX1R antagonists approved for clinical use, fueling demand for novel compounds that act at this target. In this study, we meticulously curated a dataset comprising over 1300 OX1R ligands using a stringent filter and criteria cascade. Subsequently, we developed highly predictive quantitative structure-activity relationship (QSAR) models employing the optimized hyper-parameters for the random forest machine learning algorithm and twelve 2D molecular descriptors selected by recursive feature elimination with a 5-fold cross-validation process. The predictive capacity of the QSAR model was further assessed using an external test set and enrichment study, confirming its high predictivity. The practical applicability of our final QSAR model was demonstrated through virtual screening of the DrugBank database. This revealed two FDA-approved drugs (isavuconazole and cabozantinib) as potential OX1R ligands, confirmed by radiolabeled OX1R binding assays. To our best knowledge, this study represents the first report of highly predictive QSAR models on a large comprehensive dataset of diverse OX1R ligands, which should prove useful for the discovery and design of new compounds targeting this receptor.</p></div>\",\"PeriodicalId\":72302,\"journal\":{\"name\":\"Artificial intelligence chemistry\",\"volume\":\"2 1\",\"pages\":\"Article 100040\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2949747723000404/pdfft?md5=43fcbc13b8cafbb292e0ad47efa38a38&pid=1-s2.0-S2949747723000404-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Artificial intelligence chemistry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949747723000404\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Artificial intelligence chemistry","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949747723000404","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
奥曲肽 1 受体(OX1R)是一种 G 蛋白偶联受体,通过与神经肽奥曲肽 A 和 B 的相互作用调节多种生理过程。然而,目前还没有任何选择性 OX1R 拮抗剂被批准用于临床,这就加剧了对作用于这一靶点的新型化合物的需求。在这项研究中,我们通过严格的筛选和标准级联,精心策划了一个包含 1300 多种 OX1R 配体的数据集。随后,我们利用随机森林机器学习算法的优化超参数以及通过递归特征消除和 5 倍交叉验证过程筛选出的 12 个二维分子描述符,开发出了具有高度预测性的定量结构-活性关系(QSAR)模型。通过外部测试集和富集研究进一步评估了 QSAR 模型的预测能力,证实了其较高的预测能力。我们通过对药物库数据库进行虚拟筛选,证明了最终 QSAR 模型的实际应用性。通过放射性标记的 OX1R 结合实验,我们发现了两种美国 FDA 批准的药物(isavuconazole 和 cabozantinib)是潜在的 OX1R 配体。据我们所知,这项研究首次报告了在一个包含多种 OX1R 配体的大型综合数据集上建立的高度预测性 QSAR 模型,这将有助于发现和设计靶向该受体的新化合物。
Machine learning models to predict ligand binding affinity for the orexin 1 receptor
The orexin 1 receptor (OX1R) is a G-protein coupled receptor that regulates a variety of physiological processes through interactions with the neuropeptides orexin A and B. Selective OX1R antagonists exhibit therapeutic effects in preclinical models of several behavioral disorders, including drug seeking and overeating. However, currently there are no selective OX1R antagonists approved for clinical use, fueling demand for novel compounds that act at this target. In this study, we meticulously curated a dataset comprising over 1300 OX1R ligands using a stringent filter and criteria cascade. Subsequently, we developed highly predictive quantitative structure-activity relationship (QSAR) models employing the optimized hyper-parameters for the random forest machine learning algorithm and twelve 2D molecular descriptors selected by recursive feature elimination with a 5-fold cross-validation process. The predictive capacity of the QSAR model was further assessed using an external test set and enrichment study, confirming its high predictivity. The practical applicability of our final QSAR model was demonstrated through virtual screening of the DrugBank database. This revealed two FDA-approved drugs (isavuconazole and cabozantinib) as potential OX1R ligands, confirmed by radiolabeled OX1R binding assays. To our best knowledge, this study represents the first report of highly predictive QSAR models on a large comprehensive dataset of diverse OX1R ligands, which should prove useful for the discovery and design of new compounds targeting this receptor.